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Abstract
Protein-protein interactions are critical determinants in biological systems. Engineered proteins binding to specific areas on
protein surfaces could lead to therapeutics or diagnostics for treating diseases in humans. But designing epitope-specific
protein-protein interactions with computational atomistic interaction free energy remains a difficult challenge. Here we
show that, with the antibody-VEGF (vascular endothelial growth factor) interaction as a model system, the experimentally
observed amino acid preferences in the antibody-antigen interface can be rationalized with 3-dimensional distributions of
interacting atoms derived from the database of protein structures. Machine learning models established on the
rationalization can be generalized to design amino acid preferences in antibody-antigen interfaces, for which the
experimental validations are tractable with current high throughput synthetic antibody display technologies. Leave-one-out
cross validation on the benchmark system yielded the accuracy, precision, recall (sensitivity) and specificity of the overall
binary predictions to be 0.69, 0.45, 0.63, and 0.71 respectively, and the overall Matthews correlation coefficient of the 20
amino acid types in the 24 interface CDR positions was 0.312. The structure-based computational antibody design
methodology was further tested with other antibodies binding to VEGF. The results indicate that the methodology could
provide alternatives to the current antibody technologies based on animal immune systems in engineering therapeutic and
diagnostic antibodies against predetermined antigen epitopes.
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Introduction
Antibody has become the most prominent class of protein
therapeutics and diagnostics [1,2]. However, the underlying
protein recognition principles have yet to be understood to the
level, whereby an antibody-antigen recognition interface can be
designed de novo. Although powerful high throughput recombinant
protein library techniques capable of exploring more than one
billion sequence variants in a single experiment have been
providing platforms for protein-protein interaction engineering
[3,4,5], the experimental capabilities are nevertheless infinitesimal
in comparison with the vast combinatorial sequence space in a
typical protein-protein interaction interface. Hence, current
antibody discoveries are largely limited by the uncontrollable
animal immune systems [6].
Computational capabilities on antibody design have been
demonstrated to explore sequence space than is possible
experimentally, but the focus has been largely limited on affinity
maturation of existing antibody-antigen interactions. It has been
shown that, with iterative computational design procedure
focusing on single mutations, affinity of two antibodies has been
improved by one to two orders of magnitude [7]. Computational
antibody-antigen complex models have also been used in
combination with phage display mutagenesis on a few selected
CDR residues to improve antibody binding affinity by two orders
of magnitude [8]. High-affinity antibodies can also be further
improved by one order of magnitude with structure-based
computational design [9]. De novo paratope design on antibodies
against any targeted epitope of an antigen has been developed
with computational modeling of CDR structures against the
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33340selected epitope [10], but the experimental verification of the
computational capability has yet to be demonstrated.
Successful de novo computational designs on protein-protein
interactions has been established, indicating that the current
computational methodologies on protein structural energetics are
able to identify feasible designs among vast possibilities [11](seealso
reviews [12,13] and references therein). Nevertheless, the accuracy
of current energetic functions [7,12,13,14,15,16,17] has been a
formidable barrier [18]. In particular, calculating interaction
energetics involving water molecules in protein complex formation
has been difficult [12,16,17,18,19,20,21,22,23,24,25]. As a conse-
quence, the capability of ranking a series of tentative sequences near
the optimal designs for protein-protein interface remains a difficult
challenge [11].
Experimental platforms based on phage display of synthetic
antibody libraries provide rich information on antibody-antigen
interactions [5]. In this work, the aim is to use the data generated
from phage-displayed antibody libraries to develop and calibrate
computational tools for rational design of antibodies. To this end,
we first exhaustively identified the interface CDR (complemen-
tarity determining region) sequence preferences in an antibody-
VEGF (vascular endothelial growth factor) interaction system with
experiments based on phage-displayed recombinant antibody
libraries, and then used a structural informatics-based system to
rationalize the CDR sequence preferences at atomic resolution
with computational molecular modeling. The rationalization led
to insights for a machine learning methodology, aiming at
designing interface CDR sequences against designated epitopes
on antigens of known structure. The results suggest that
computational antibody design could effectively empower the
high throughput recombinant protein library-based technologies.
Results and Discussion
Experimental antibody-VEGF interface sequences
The experimental amino acid preferences of antibody CDRs
binding to VEGF were elucidated with VEGF-binding scFv/sc-
dsFv variants derived from the G6 Fab-VEGF complex [26] as a
model system. Nine synthetic scFv (single chain variable fragment
[4]) or sc-dsFv (single chain disulfide stabilized variable fragment
[27]) libraries were constructed with a recombinant phage display
system to systematically randomize 5 consecutive residues on each
ofthe 6CDRsonthe variabledomains[27];more than500 variants
for which the scFv/sc-dsFv expressed on bacterial phage surfaces
are able to bind to VEGF with high affinity were systematically
discovered with high throughput phage display selection and
screening [27,28]. The amino acid preferences of the 30 CDR
interface residues in the scFv variants binding to VEGF are shown
in Figure 1(a); the VEGF-binding data and the sequence details of
the selected variants are shown in Table S1. Figure 1(b) and Table
S2 show the VEGF-binding sequence patterns in sc-dsFv variants
obtained with the corresponding sc-dsFv libraries. As shown in
Figure 1(c), the amino acid preferences are position-dependent; a
cluster of interface positions forms the core interface region, where
amino acid type conservation for antigen binding is much more
stringent than the peripheral interface.
Since the phage display systems in Figure 1 are based on the scFv
and the sc-dsFv scaffolds, it is important to verify that both the scFv
and the sc-dsFv structures are similar to the variable domain
structure in G6-Fab even in the absence of the two Fab constant
domains in the scFv or the sc-dsFv structures. High-resolution sc-
dsFv structure with the sequence identical to the parent G6-Fab
variable domains (except for the two interface cysteines in the sc-
dsFv shown in Figure 2) has been elucidated with x-ray
crystallography as shown in Figure 2 (PDB code 3AUV); the
refinement data are shown in Table S3. The corresponding scFv
structure has not been attainable experimentally due to high
aggregation tendency of the scFv in crystallization conditions. The
comparison of the antibody variable domains in the uncomplexed
and the VEGF-complexed G6-Fab structure (obtained from 2FJF
and 2FJG, respectively, in PDB) with the sc-dsFv structure shown in
Figure 2 suggests that the variable domain structures in the G6-Fab
and in the sc-dsFv are largely identical to the atomic details. The
structural differences of the engineered interface disulfide bond
unique to the sc-dsFv structure are also highlighted in Figure 2.
Although the G6-derived scFv structure has not been determined
with experimental method, the consistency of the sc-dsFv structure
with the G6-Fab structure as shown in Figure 2 and the consistency
of the sequence patterns for the scFv and sc-dsFv variants bindingto
VEGF (comparison of Figures 1(a) and 1(b)) indicate that the scFv-
VEGF interactions can be modeled based on the G6 Fab-VEGF
complex structure as well.
The scFv/sc-dsFv libraries were designed with an internal
control in each of the libraries to ensure that the amino acid
preferences derived from the VEGF-binding variants are relevant
to the complex structure, even when some of the CDR residues in
the antibody fragment variants are different from the template G6-
Fab sequence. As shown in Figure 1, each of the scFv/sc-dsFv
libraries (except for the H1 library) was constructed with two
separate random sequence regions simultaneously: one of the
randomized regions contains 5 consecutive degenerate codons
(NNK) in one of the four CDRs – CDR1L, CDR2L, CDR3L, and
CDR2H; the other randomized region always contains 5
consecutive variable positions (also diversified with the NNK
degenerate codon) in CDR3H. This design is based on the prior
knowledge that the binding of the G6-derived scFv/sc-dsFv with
VEGF is primarily anchored with the residues in CDR1H and
CDR3H [27,28]. With the residues in CDR1H remain constant as
in G6-Fab in all the variants of the libraries (except for H1 library
where the CDR3H residues remain constant as in G6-Fab),
VEGF-binding sequence patterns emerged for the CDR3H
variable region served as an indication to verify if the antibody-
VEGF complex structure remains relevant for the selected variants
in binding to the VEGF. As shown in Figures 1(a) and 1(b), the
sequence patterns of the CDR3H region for the variants binding
to VEGF are all in good agreement in the conservation of the
anchoring residues in CDR3H (F101, F102, and L103), suggesting
that the sequence variations in the CDRs for the scFv/sc-dsFv
variants binding to VEGF did not variegate substantially the
binding mode of the antibody variable domains to VEGF, mostly
due to the anchoring of the scFv/sc-dsFv variants onto the VEGF
binding site with the conserved anchoring residues in the CDR3H
and CDR1H. Moreover, competition test of the phage-displayed
scFv binding to VEGF with soluble non-fusion G6-derived scFv
indicated that 34 out of the 37 selected phage displayed scFvs from
the L2H3 library (Table S1) showed clear competition by the
soluble scFv (up to 4 mM) on VEGF-binding, assuring that the
scFv variants shown in Figure 1 bind to VEGF at mostly the same
binding site as in the G6-Fab-VEGF complex. Taken together, the
amino acid sequence preferences (LOGOs in Figure 1) for all the
CDR positions in consideration are consistently relevant to the
model antibody-antigen complex structure.
Rationalization of the interface CDR sequence
preferences
The amino acid preferences of the scFv interface CDRs binding
to VEGF, as shown in Figure 1(a), are quantitatively represented
by Wji (shown in Table 1), which is the log-odd-ratio of the
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background probability of the amino acid type in the phage
display system (Equation (5) in Methods). The working hypothesis
is that Wji is linearly correlated with one or a combination of the
following three statistically derived log-odd-ratio terms: Xji, Yji, and
Zji (Equations (1),(4) in Methods), where Xji is the upper bound of
the atomistic contact term for amino acid i at position j; Yji reflects
the maximal desolvation energy penalty due to the amino acid i at
position j in forming the protein-protein complex; Zji is the
structural propensity for amino acid i in position j of the antibody
CDR. One first-order approximation embedded in the working
hypothesis is that the amino acid preferences (Wji) of position j is
intrinsically dependent on the local antibody-antigen structural
environment around the position j; higher order cooperative
interactions due to the neighboring CDR residues are intractable
in this approach. Following this approximation, the Xji and Yji
terms were calculated with the antibody structural models where
the interface CDR position j was enumerated with all rotamers of
amino acid type i while all other positions were reduced to alanine,
as described in Equations (1),(4) in Methods, so as to mimic
realistic antibody design situations where CDR sequences are not
known. The numerical results of Wji, Xji, Yji, and Zji are shown in
Table S4.
The working hypothesis was tested by calculating the Pearson
correlation coefficients (cc) between Wji and Xji,Y ji,Z ji respectively
for all amino acid type i in each of the position j. The results are
shown in Table S4 and are summarized in Figure 3. In Figure 3(a),
the 30 interface CDR amino acids are shown color-coded based
on the Wji-Xji correlation coefficient. The background VEGF
interface in Figure 3(a) is also color-coded according to the statistic
strength reflecting the average atomistic contact terms calculated
for each of the VEGF interface atoms with model scFv structures
constructed based on the antigen-binding CDR sequences listed in
Table S1 (detailed method described in Text S1). The experi-
mental amino acid preferences Wji are significantly and positively
correlated with the atomistic contact term Xji in the core interface
positions: Y32-H in CDR1H (cc=0.51), W33-H in CDR1H
(cc=0.67), F101-H in CDR3H (cc=0.40), F102-H in CDR3H
(cc=0.30), A32-L in CDR1L (cc=0.42), F53-L in CDR2L
(cc=0.54), Y92-L in CDR3L (cc=0.34). These positions are
consistent with the positions in the core interface region as shown
in Figure 1(c) and are located at or near the VEGF interface sub-
area colored in red (Figures 1(c) and 3(a)); the color code indicates
that this VEGF area is consistently used to make energetically
favorable contacts to the binding scFv variants. The energetics
governing interactions in this core interface region is closely
related to the energetics governing the stability of the interior of
protein structures, for which the statistics are used for Xji
calculations. The ranking capabilities of Xji on the amino acid-
protein contact energetics for residues in the core interface are
largely comparable to the consensus of 24 publicly available
scoring functions devised for computational drug design (Tables
S5(a) and S5(b)). This comparison also highlights the diverse
ranking results among these 24 scoring functions.
The sub-area color-coded red on VEGF interface in Figure 3(a)
is in good agreement with the ‘hot spots’ on VEGF (F17-W, M18-
Figure 1. CDR sequence profiles and distribution of the amino acid preference stringency in the scFv-VEGF binding. (a) The data were
derived from the screening of the five scFv libraries (L3H3, H2H3, L2H3, L1H3, and H1, see also Table S1). The computation of the LOGO plots is based
on the formulation by Gorodkin et al [53] with modifications for amino acid background probabilities in phage display libraries and for pseudo counts
as shown in Equation (2) of Text S1. (b) The data were derived from the screening of the four sc-dsFv libraries (L3H3-S5, H2H3-S5, L2H3-S5 and L1H3-
S5, Table S2). (c) The interface structure of the antibody-VEGF is depicted based on the G6-Fab-VEGF complex structure (2FJG), where the 30 CDR
interface residues are shown in stick model and the VEGF homodimer structure (V and W chains) shown in sphere model. The distribution of the
color-coded CDR residues shows the position-dependence of the amino acid preferences towards VEGF-binding. The core interface region (boxed in
red square) contains residues with high stringency in amino acid type requirement comparing with the residues in the peripheral interface region.
The CDR residues are color-coded based on the information content (Ij, as shown in the y-axis of the panel (a), is defined in Equation (2) of the Text
S1). The color code for the background VEGF molecule is described in Figure 3(a).
doi:10.1371/journal.pone.0033340.g001
Figure 2. The crystallographic structure of the sc-dsFv derived from G6-Fab. The sc-dsFv structure (colored in green, PDB code 3AUV) is
superimposed with the variable domains of VEGF-complexed G6-Fab (2FJG in PDB code, colored in grey) and unbound G6-Fab (2FGF in PDB code,
colored in magenta). The interface disulfide bond in the sc-dsFv is marked with the arrow. The RMSDs between the sc-dsFv and the variable domains
derived from 2FJF and 2FJG are 0.629 A ˚ and 0.942 A ˚, respectively. The model of the interface disulfide bond in the sc-dsFv is shown with the
superimposition of the Fo-Fc simulated annealing omit density map (colored in cyan) at the 5.0s level. The omit density map was calculated without
the residues of the interface cysteins. The refinement data for the sc-dsFv structure determination are shown in Table S3.
doi:10.1371/journal.pone.0033340.g002
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PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e33340Table 1. Comparison of the predicted and the experimental amino acid preferences at each of the CDR interface positions.
28-L 29-L 30-L 31-L 32-L
Wji pWji-ti Wji pWji-ti Wji pWji-ti Wji pWji-ti Wji pWji-ti
P3.9 S .61 P4.2 D. 4 2 G3.4 S .65 G4.3 R. 8 5 R4.2 F .43
A2.8 N .56 G2.4 A. 2 8 F2.1 A. 5 7 P3.7 S .68 A2.4 Y .42
S1.4 P .47 M2.1 N .18 S1.7 N. 3 6 N1.0 A. 5 7 Y1.1 H .37
E1.0 F. 4 0 H1.0 T .13 A1.5 H .31 T0.2 H .49 W1.0 N .36
M1.0 A .19 I1.0 R .10 P1.5 P .23 G .30 G0.9 G .25
T0.9 H .17 T0.9 L .08 L. 1 8 N .20 T0.2 T .14
V0.2 E .07 L0.5 H .07 Y .07 Y .07 R. 0 6
M .00 A0.2 I .05 G .02 A .00
P. 0 4 R .01
50-L 51-L 52-L 53-L 54-L
Wji pWji-ti Wji pWji-ti Wji pWji-ti Wji pWji-ti Wji pWji-ti
E2.5 Y .43 A3.6 N/A N2.5 N/A H4.4 R .59 H3.3 N/A
G2.0 G .37 S2.8 W2.5 Y4.0 N .56 N2.5
R1.8 S .37 K1.4 L1.8 F3.9 G .38 L1.8
S0.9 R .33 M1.4 S1.8 M2.5 S .34 I1.4
Q0.6 H .30 G1.4 H1.4 I1.4 A .33 S1.4
T0.6 N .26 T1.4 K1.4 W1.4 H. 2 1 P1.4
L0.4 A .21 R0.4 D .17 R0.9




92-L 93-L 94-L 95-L 96-L
Wji pWji-ti Wji pWji-ti Wji pWji-ti Wji pWji-ti Wji pWji-ti
F4.3 A .93 K4.9 S. 6 5 P2.9 R. 6 8 P3.2 N/A H5.7 N/A
Y3.6 S .60 N3.9 H. 5 8 R1.6 L .66 K1.6 Y2.4
H3.0 P .38 M3.5 G .45 A1.5 Y .36 N1.6 F2.4
N3.0 N .35 I3.0 A .29 G1.1 N .30 S1.6 P2.0
I2.4 H .25 R1.6 N .27 H0.5 H .29 T1.5 M1.6
S2.1 F .19 T1.1 R. 2 4 I0.5 G. 2 5 A1.1 N0.5
L1.2 Y .13 S0.9 P .05 T0.5 A. 1 8 F0.5 E0.5
S0.01 S .17 A0.5
29-H 30-H 31-H 32-H 33-H
Wji pWji-ti Wji pWji-ti Wji pWji-ti Wji pWji-ti Wji pWji-ti
I4.9 N/A D5.2 S .56 D8.0 S .41 Y8.3 Y .52 W9.1 Y .45
L4.2 E4.9 P. 2 4 N5.5 P. 1 3 F6.9 F .44 F4.1 G .44
M3.0 N3.0 D .22 E3.0 N. 0 1 H .41 H .32
V2.9 S1.8 A .19 H2.2 P .28 N .26
F2.2 Y1.2 H .18 N .27 A .19
R0.03 N .14 A .23 R .19
R. 0 2 S .17
E. 0 1
53-H 54-H 55-H 56-H 57-H
Wji pWji-ti Wji pWji-ti Wji pWji-ti Wji pWji-ti Wji pWji-ti
K2.2 D .51 P5.5 P .60 P3.1 P .42 P5.5 G .59 P4.3 Y. 6 3
L2.0 Y .38 N2.2 E. 5 1 D2.2 E .36 D2.7 P .14 A1.9 F .60
N1.6 P .28 T1.9 A .26 N2.2 A .28 I1.6 H .14 S1.1 M. 4 7
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frequently buried in the interior of the interface. As shown in
Figure 3(b), 5 (Y32-H, W33-H, F101-H, F102-H, and Y92-L) core
interface CDR positions are buried in the interface with more than
39% SASA change. In addition, 4 (Y32-H, W33-H, F101-H, and
F102-H) out of these 5 buried interface positions are also highly
conserved in the sequence patterns (Figure 1). Theses conserved
interface residues resemble key residues involving in core
structures of tightly packed protein interiors.
Amino acid preferences in the peripheral interface positions are
less pronounced but are not indifferent (Figure 1 and Table 1); the
sequence preferences of these positions cannot be explained with
the structural propensities measured by Zji or by the atomistic
contact term Xji. Figure 3(c) shows the interface residue structures
color-coded based on the Wji-Zji correlation coefficients. The
amino acid preferences in all the 30 interface positions are
correlated with the local structural propensities to various extents,
but the correlations do not distinguish the core interface region
from the peripheral region in the CDR interface.
Amino acid preferences in the peripheral regions are mostly
governed by hydration-mediated interactions, as measured by the
Yji term. The residues with the most prominent Wji-Yji correlation
are D28-L in CDR1L (cc=0.40), S30-L in CDR1L (cc=0.27),
S30-H in CDR1H (cc=0.42), P53-H in CDR2H (cc=0.31), A54-
H in CDR2H (cc=0.47). All these residues are in the peripheral
interface regions. As shown in Figure 3(d), the interface CDR
residue structures color-coded based on the Wji-Yji correlation
coefficients are essentially a mirror image to the color-codes shown
in Figure 3(a) for the Wji-Xji correlation. This indicates that
minimizing the desolvation penalties, in contrast to optimizing the
contact energy as in the core interface region, is the major
determinant for the amino acid preferences in the peripheral
interface CDR positions.
Figure 4 shows the hydration patterns on VEGF and the
antibody CDRs. The core interface regions on the VEGF and the
corresponding part of the antibody CDRs are much less hydrated
than the other surface regions, suggesting that the core interface
region in an epitope-paratope pair can be identified with the
hydration pattern predictions as shown in Figure 4. Together, the
results shown in Figures 3,4 suggest that the core interface
region, composed of only a few less solvated hot-spot residues on
the antigen surface, is recognized by a few contact-driven residues
on the CDRs of the antibody, forming the core of the antibody-
antigen recognition interface without substantial energetic penalty
due to the dehydration of the core interface. The energetics for this
core interface assembly resembles that governing the stability of
the interior of protein structures. The CDR positions surrounding
the core interface prefer small hydrophilic sidechains over the
possibility of forming specific inter-protein van der Waals
interactions and hydrophobic contacts. Hydration-mediated
interactions indirectly linking the hydrophilic groups in both sides
of the protein interface surrounding the core interface region
provide non-specific but weak adhesive driving force for the
interface, explaining the non-specific preferences for small and
hydrophilic amino acid sidechains in these positions. Bulky
hydrophobic sidechains that abolish this weak interaction and
Table 1. Cont.
53-H 54-H 55-H 56-H 57-H
Wji pWji-ti Wji pWji-ti Wji pWji-ti Wji pWji-ti Wji pWji-ti
G1.6 H .27 N .17 G2.2 D .20 V0.3 N .13 F0.9 N .40
P1.2 E .16 H .11 H1.6 G. 0 8 S0.2 D0.9 R. 2 8
T0.3 N. 0 4 D .06 I1.6 N .01 H0.9 H .23
S .02 F0.9 E0.9 Q .18





101-H 102-H 103-H 104-H 105-H
Wji pWji-ti Wji pWji-ti Wji pWji-ti Wji pWji-ti Wji pWji-ti
F7.3 P. 5 9 F7.5 L. 5 0 L5.8 R .47 N4.3 A. 4 2 G5.8 G .42
W5.4 F. 4 8 Y6.8 G .43 A0.5 G .34 G2.0 H .33 N1.6 A .38
H3.9 Y .35 M0.5 D .32 Y .31 Q2.0 P .30 S0.9 R. 3 6
M1.6 N .32 P .29 N .29 F1.6 G .29 Y0.6 Y .24
E .31 N .22 P .26 H1.6 Y .27 H0.5 N .20
D .30 H .20 H .25 R1.6 N .19 H .16
L. 2 0 F .17 A .16 S0.9 F .19 L. 1 0
H. 1 2 E. 0 3 L .04 Y0.6 R .16 S .05
A. 0 6
M. 0 2
D0.5 S. 1 0
L. 0 5
At each position, the left-hand column shows the amino acid type and the corresponding Wji. All the predicted positive amino acid types (dpWji=1) and the activation
values for sequence preference (pWji) are shown in the right-hand column. The amino acid types shown in bold are the common amino acid types (true positives)
shown in both the left-hand and the right-hand columns.
doi:10.1371/journal.pone.0033340.t001
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PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e33340Figure 3. Structure-dependent determinants for the amino acid preferences Wji. (a) The interface structure of the antibody-VEGF depicted
in this panel is attained from the G6-Fab-VEGF complex structure (2FJG). The 30 CDR interface residues are shown in stick model, and the VEGF
homodimer structure (V and W chains) is shown in sphere model, where some of the residues are labeled according to the numbering in 2FJG. The
CDR interface residues are color-coded based on the Wji-Xji correlation coefficients, for which data for the correlation computation are listed in Table
S4. As shown by the bar for color-codes at the bottom of the panel, the residue positions with positive correlation are shown in red and negative
correlation are shown in blue. CDR positions that are too distant to make any contact with VEGF are colored in yellow. The VEGF atoms in the
interface are colored with increasing redness to highlight the atoms interacting with the antibody variants (method described in Text S1) through
increasingly stronger interactions embedded in the Xji terms, which are derived from the atomistic contact statistics in protein interiors. (b) The 30
CDR interface residues are color-coded in terms of the ratio of the solvent accessible surface area (SASA) change upon the antibody-VEGF complex
formation over the solvent assessable surface area in the absence of the VEGF. (c) The CDR interface residues are color-coded according the Wji-Zji
correlation coefficients. (d) The CDR interface residues are color-coded according the Wji-Yji correlation coefficients. CDR positions that are too distant
Rationalization and Design of Antibody CDRs
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peripheral interface region.
Although protein-protein core interfaces anchored by hot spots
[29,30,31] and the hydration-mediated interactions in the
peripheral protein-protein interface regions [18,21,22,23,24] have
been well-established qualitatively, the results shown in Figure 1
nevertheless provide rich information on the amino acid
preferences for the positions in each of the interface regions.
More importantly, the new information led to insights at atomic
resolution for quantitative evaluations of the amino acid
preferences in the interface positions (Figure 3). Computational
algorithms based on these quantitative insights should be useful in
designing antibody CDR sequences targeting at a designated
epitope of known structure (see below).
Machine learning models for computational antibody
desig
The results above suggest that the Xji,Y ji,Z ji terms should be
useful in predicting the amino acid preferences in the CDR
interface. We chose the minimal logistic regression model with
weighted sum of the Xji Yji and Zji terms as input (Equation (4) in
Methods) to predict the amino acid preferences at each of the
interface CDR positions contacting the antigen (24 positions, not
including the 6 non-contact positions as colored in yellow in
Figure 3(a) and (d)). The rationale is that the Xji,Y ji,Z ji terms
should carry enough information to evaluate as to what extent an
amino acid type i is suitable for an interface environment
surrounding the position j. The machine learning was carried
out by training one logistic regression model for each of the 20
amino acid types at each of the 24 CDR positions; the amino acid
preferences at each of the interface positions were predicted with
the 20 logistic regression models trained with information from all
other 23 positions and the binary predictions (dpWji in Equation
(4)) were assessed with the positives and negatives determined
experimentally for the position (leave-one-out cross-validation so
that the training set does not include the test case). The weights of
the trained models and the prediction results are shown in Table
S4.
The logistic regression model was chosen because of the
simplicity of the weighted linear combination of the Xji Yji and Zji
terms as input. The linear combination requires only small
number of parameters (each model requires only 5 variable
parameters; see Equation (4) in Methods). In contrast, in more
sophisticate machine learning models, such as artificial neural
network or support vector machines, each model would frequently
require tens to hundreds of weight parameters. These machine
learning models are not suitable for the application in this work
because the number of available data points is relatively too small
for the machine learning models. The regression algorithm using
23 data points to optimize 5 variable parameters is chosen so as to
avoid over-fitting of the machine learning models.
The effectiveness of the amino acid preference prediction by the
logistic regression models is summarized in Table 1. In practice,
positive Wji (observed count for amino acid i at position j is greater
than the anticipated frequency of amino acid i encoded in the
degenerate codon NNK) for amino acid type i is considered as
positive (dWji=1) in position j, and the predicted positive amino
acid types (dpWji=1) have the output activation value (pWji) from
the logistic regression models greater than the threshold ti
(Equation (4)). The overall Matthews correlation coefficient
(MCC, Equation (10)) for the amino acid preference binary
predictions (leave-one-out cross validation) of the 20 amino acid
Figure 4. Hydration patterns on the surface of VEGF and the antibody. (a) Hydration patterns of VEGF are shown as the water oxygen atom
PDM contours in cyan on the protein surface and as the color-coded atom surfaces. The water PDMs are shown as 0.0019 contours in this panel. The
atom surfaces are color-coded according to the hydration pattern near the atom (Equation (3) in Text S1). (b) The hydration pattern for the G6-Fab
(2FJG) is shown.
doi:10.1371/journal.pone.0033340.g004
to render the Yji term becoming independent of the amino acid type i are colored in yellow. The VEGF atoms are color-coded according to the
hydration pattern as shown in Figure 4(a). (e) The CDR interface residues are color-coded according the correlation coefficient of Wji versus (pWji-t i)
(confidence level of predicted amino acid preference for amino acid i at position j). The background VEGF atoms are color-coded as in Figure 4(a).
doi:10.1371/journal.pone.0033340.g003
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the experimental and prediction data shown in Table 1. The
MCC for random predictions would be zero and perfect
predictions would yield MCC of one. On average, each interface
position has 5.762.0 positive amino acid types; 7.762.0 amino
acid types are predicted positive on average at each position and
3.561.9 amino acid types are true positive on average at each
position – the accuracy, precision, recall (sensitivity) and specificity
(Equations (6),(9) in Methods) of the overall binary predictions
are 0.69, 0.45, 0.63, and 0.71 respectively. In comparison, a
random prediction of 5.7 residues for each of the 24 positions
would yield 0.59, 0.29, 0.29, and 0.72 for the same set of
prediction effectiveness measurements.
The prediction accuracies (Wji2(pWji2ti) correlation coeffi-
cients) shown in Figure 3(e) are inversely correlated (cc=20.40)
with the SASA change shown in Figure 3(b) and are positively
correlated (cc=0.25) with Wji-Yji correlation coefficient
(Figure 3(d)). This suggests that, in general, the yjiYji term in
Equation (4) gives more weight in determining pWji and thus the
sequence preference predictions are more accurate for the
peripheral interface positions.
The machine learning models above enabled a formal statistical
extrapolation with accuracy to an extent, providing suggestions on
optimal CDR sequences capable of binding to a designated
epitope based on rules learned from a limited set of data. The
phage display data have provided invaluable but nevertheless
incomplete picture on the possible combinations of CDR residues
in recognizing the epitope on the antigen. Even the limited
sequence space of the CDR variants selected for binding to the
same epitope on VEGF could not be completely explored with
only several hundreds of selected and confirmed binders as shown
in Figure 1; many of the amino acid combinations that have not
been observed from the limited sampling remain uncertain. The
logistic regression models above have enabled a better use of the
limited dataset in predicting optimal CDR sequences unseen
previously in an antibody-antigen interface.
Further tests of the prediction of optimal CDR residues in
other antibody-antigen interfaces
The capabilities of the machine learning models were further
tested with other antibody-VEGF complex interfaces, where the
anti-VEGF antibody sequences are different with different
corresponding epitope on the antigen. Two of these complex
interfaces (1BJ1 [32] and 2FJH [26]) have been optimized for high
affinity, while the other three anti-VEGF antibodies (2QR0 [33],
1TZH and 1TZI [34]) were selected from phage display libraries
with only limited amino acid variations (Y, S, D, A) in selected
CDR residues. Since the corresponding phage display variant
profiles as shown in Figure 1 are not available from the associated
studies, similar analyses shown in Figure 3 could not be carried
out. Alternatively, we predicted the ranking of the 20 natural
amino acid types in each of the CDR positions defined in the
respective antibody-antigen complex structures and highlight the
rank of the CDR amino acids in the crystal structures based on the
ranking predicted with the trained logistic regression models
(Figure 5). It is not known from experimental data as to if there
exist other more optimal amino acid types in comparison with the
corresponding amino acid type in the structure, but nevertheless,
we assume that amino acids in the structures with better ranks are
predicted more accurately. Figure 5 depicts the summary of the
predictions, and the details of the prediction results are shown in
Table S9.
As shown in Figures 5(a) and 5(b) for complex 1BJ1 and 2FJH
respectively, the Tyr residues in the core interface were predicted
with high accuracy, while the core Trp residues were predicted
incorrectly. It is of interest to compare the results with those of the
three antibody-antigen interfaces where the antibodies are
members of minimalist antibody libraries with limited amino acid
variations (Y, S, D, A) in the CDR residues (Figures 5(c), 5(d), 5(e)
for complex 2QR0, 1TZH, 1TZI respectively). Among the
residues in these core interfaces, only one Tyr residue was poorly
predicted in the complex 1TZH. It is evident that the minimalist
antibody library designs have not only substantially reduced the
complexity space of the CDR regions, the computational antibody
design herein can be better applied to a system with less complex
combinatorial selections.
Overall, the sequence preferences in the peripheral regions of
the antibody-antigen interfaces were better predicted than the core
regions. Figure 6 summarizes the distribution of the predicted
ranking of the amino acids in the complex structures. The amino
acids in the peripheral interface regions are generally predicted
with better ranking (distribution in red in Figure 6) in comparison
with the predictions for the amino acids in the core interface
regions (distribution in blue in Figure 6). Both distributions of
predicted ranking are better than random distribution shown as
the flat dashed line in the figure. These are in agreement with the
benchmark results shown above in Figure 3.
Computational recombinant antibody library design
The prediction algorithm can be used to design antibodies
against epitopes of known structure. The peripheral interface
sequence preferences can be predicted to an extent with the
trained machine learning models above. The sequence preference
predictions for these regions are more accurate and these positions
are more tolerant in amino acid preference prediction errors
(Figure 1 and 3). The core interface CDR sequences can be better
predicted with the Xji term alone (Figure 3(a)). However, these
CDR core interface designs need to be validated with focused
experiments because of the high stringency of sequence prefer-
ences in this area. To this end, the core interface CDR residues
would be encoded with degenerate codons biased towards
aromatic and hydrophobic amino acid types so as to form protein
interior-like interactions with the hot-spot residues on the antigen.
As such, the designed synthetic DNA libraries are confined to the
experimental limit of about one billion variants for phage display
because the number of the core interface residues encoded by
degenerate codons would be likely less than 10.
The results above suggest a methodology for computational
design of synthetic antibody libraries for high-throughput antibody
discovery platforms. First, the antibody binding site (epitope) on
the antigen containing hot-spot residues with sparse hydration
patterns (methodology as shown in Figure 4 and Text S1) is
defined. Models of the antibody-antigen complex structures with
only mainchain structure for the CDR interface residues targeting
the selected epitopes are constructed with computational molec-
ular modeling and docking of the antibody and antigen structures.
The CDR interface residues on the antibody near the antigen hot-
spot residues are the core interface residues; the rest of the CDR
residues are peripheral interface residues. The amino acid types
and rotameric conformations are enumerated at each of the CDR
positions to predict the amino acid preferences for the peripheral
and the core CDR positions with the machine learning models.
Antibody libraries designed based on the model complex
structures, the peripheral sequence preferences, and the core
interface residue libraries can then be selected and screened with
the standard high throughput phage display platform, which has
been used in attaining results shown in Figure 1. The antibody
library design methodology will further mature with extended
Rationalization and Design of Antibody CDRs
PLoS ONE | www.plosone.org 9 March 2012 | Volume 7 | Issue 3 | e33340Figure 5. Predicted ranking of the CDR amino acids in the antibody-VEGF complex interfaces. Panel (a) to (e) shows the complex
structure for 1BJ1, 2FJH, 2QR0, 1TZH, and 1TZI respectively. In each of the panels, the atoms of the antigen VEGF are shown in spheres; the VEGF
atoms colored in magenta are core interface atoms and the VEGF atoms colored in cyan are rim interface atoms. The core-rim assignment follows the
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have been well-established [5]. The structure-based in silico design
of recombinant antibody libraries will provide alternatives to the
current animal-based antibody technologies to facilitate the
discoveries of antibody therapeutics and diagnostics and to enrich
the basic understanding of protein-protein interactions in general.
Materials and Methods
Phage display of VEGF-binding scFv and sc-dsFv
The methods for preparing anti-VEGF template scFv, scFv
phagemid, sc-dsFv phagemids, anti-VEGF scFv/sc-dsFv phages
and for scFv/sc-dsFv panning, single colony and ELISA analysis,
and interdomain disulfide bond formation analysis have been
described previously [27,28].
Expression and purification of sc-dsFv
The expression and purification of the sc-dsFv followed the
method described previously with minor modifications [35]. In
brief, the sc-dsFv coding region was subcloned into pET-32
expression vector encoding thioredoxin as a fusion protein N-
terminal to the sc-dsFv. The fusion protein contains a hexa-His tag
followed by a TEV protease cutting site between the thioredoxin
and the sc-dsFv, which is followed by an Avitag oligopeptide
(GLNDIFEAQKIEWHE, Avidity Inc., USA) appending to the C-
terminus of the sc-dsFv for in vivo biotynylation. The sc-dsFv gene
derived from phage panning was subcloned into the expression
vector via the SfiI and NotI cutting sites encompassing the sc-dsFv
coding region. E. coli Rosetta-gami B (DE3) strain culture
transformed with scFv/sc-dsFv expression vector was grown in
26 YT medium (Tryptone 16 g/L, Yeast extract 10 g/L, NaCl
5 g/L) with ampicillin (200 mg/L), tetracycline (12.5 mg/L) and
chloramphenicol (37.5 mg/L) at 30uC until OD600 reached 1.0,
and was then incubated at 20uC for another 2 hr before adding
0.2 mM IPTG. After overnight protein expression and centrifu-
gation, the cell pellets were resuspended in lysis buffer (Tris-HCl,
50 mM, pH 8.0, 150 mM NaCl, 30 mM imidazole) and the
suspended cells were then broken by Microfluidizer (Microfluidics,
MA). The recombinant thioredoxin-sc-dsFv fusion protein was
purified by nickel chelation chromatography with IMAC pre-
packed column (GE Healthcare Life Sciences) charged by 0.1 M
NiSO4 solution. The fractions containing the fusion protein were
collected and dialyzed by Tris-HCl, 50 mM, pH 7.5 (the
theoretical pI of sc-dsFv was 5.82) overnight at 4uC or desalted
by HiPrep 26/10 desalting column (GE Healthcare Life Sciences)
with the same buffer. The protein solution was then introduced to
ion-exchanged chromatography (prepacked Q column, GE Life
Healthcare Sciences). The fractions containing the thioredoxin-sc-
dsFv fusion protein were collected and treated with His6-tagged
TEV protease (A280 ratio 50:1) at 30uC for at least 5 hr but not
longer than 8 hr. The TEV-cleaved fragment containing His6-
tagged thioredoxin and the His6-tagged TEV protease were
removed by nickel chelation chromatography. The fractions
containing sc-dsFv were further purified with a Superdex75 size-
exclusion column (GE Healthcare Life Sciences) in SEC buffer
(Tris-HCl, 50 mM, pH 7.5, 400 mM NaCl, 10% glycerol). The
soluble sc-dsFv protein was prepared with 95% purity. The
purified sc-dsFv was stored at 4uC for a least one week without
affinity loss.
Crystallization of sc-dsFv
The sc-dsFv solution was concentrated to 10 mg/ml without
precipitation. Crystallization screening after PCT test (Hampton
Research) for the sc-dsFv was carried out with the protein in
6 mg/ml concentration. The crystallization screening of sc-dsFv
was carried out in MosquitoH (TTP LabTech Ltd., United
Kingdom) with screening kits from Hampton Research (Laguna
Niguel, CA) and Molecular Dimension (Apopka, FL). The purified
sc-dsFv in SEC buffer was mixed with an equal volume of the
reservoir solution (100 mM Tris–HCl, 100 mM MgCl2 and 20%
PEG4000, pH 8.0) and then crystallized at 20uC by the hanging-
drop vapor-diffusion method. The crystals appeared after one day
definition previously published [54]. The CDR atoms in the core interface are shown in thick stick model and the CDR atoms in the rim interface are
shown in thin stick model. The ranking of the CDR amino acids in the structures are color-coded according to the color bar shown at the bottom of
the figure: Better ranking is shown with increasing depth in red; worse ranking is shown with increasing depth in blue. The CDR residues colored in
yellow are not in contact with the antigen.
doi:10.1371/journal.pone.0033340.g005
Figure 6. Distributions of the predicted ranking of the CDR amino acids in the antibody-VEGF complex interfaces. The x-axis shows
the predicted ranking of the CDR amino acids in the five antibody-VEGF complex interfaces as shown in Figure 5. Detailed prediction results are
shown in Table S9. The y-axis shows the percentage of the CDR amino acids predicted with the ranking shown in x-axis. The red line shows the
distribution for the amino acids in the core interface, while the blue line shows the distribution for the amino acids in the rim interface. These two
distributions are compared with random distribution shown as the flat dash line in the figure.
doi:10.1371/journal.pone.0033340.g006
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dimension in one week. A 2.4-A ˚ X-ray diffraction data set was
collected at the beamline 13C1 of the National Synchrotron
Radiation Research Center (Hsinchu, Taiwan). Before the crystal
was mounted on the X-ray machine, the crystal was soaked briefly
in reservoir solutions containing 20% (v/v) glycerol as a
cryoprotectant. All diffraction data were indexed, integrated,
and scaled with HKL2000 package [36].
Structure determination and refinement
The crystal structure of sc-dsFv was solved by the molecular
replacement method The refinement procedure used one pair of
the variable fragment structure derived from the published Fab
structure (2FJF in PDB code [26]) as the search model and using
the software molrep [37] in CCP4 package [38]. Only one clear
solution was found and the R-work and R-free values of the initial
30 rounds of Refmac5 refinement [39] were 0.2581 and 0.3003,
respectively. The resolved structures contained six sc-dsFv
molecules in one asymmetric unit. The residues that were different
between sc-dsFv and variable fragments derived from 2FJF were
replaced automatically by MrBUMP module (Automated Model
generation and Molecular Replacement) in the CCP4 package.
The manual structural adjustment and well-ordered water
molecule placement were carried out with Coot software [40].
Iterative cycles of computational refinements were performed by
phenix-refine [41] with TLS options turned on. The TLS groups
were determined by the TLSMD server [42]. The progress of the
refinements was monitored by both of the R-work and R-free
values. The stereochemical quality of the refined structures was
checked by PROCHECK [43] within Structural Analysis and
Verification Server (NIH MBI Laboratory for Structural Geno-
mics and Proteomics, UCLA). The RMSD between each sc-dsFv
molecule in asymmetry unit, among the whole molecules or CDRs
between sc-dsFv and variable fragments derived from 2FJF or
2FJG [26] were calculated by PyMOL (The PyMOL Molecular
Graphics System, DeLano Scientific, San Carlos, CA, USA.
http://www.pymol.org). The sc-dsFv structure coordinates and
refinement data have been submitted to PDB under the code
3AUV.
Computation of Wji,X ji,Y ji,Z ji and pWji
The model antibody structures were identical to the template
structure (derived from 2FJG in PDB) except that the 30 interface
CDR residues were all replaced with alanine to mimic realistic
situations where CDR sequences were not known. To build the
sidechain of the residue at position j, the amino acid type i
adopting a rotameric structure k from the penultimate rotamer
library [44] was locally optimized with the ‘‘Clear Geometry’’
function in Discovery Studio (version 2.5, Accelrys) while the rest
of the antibody-antigen complex remained fixed. The sidechain
conformations clashing with the rest of the protein complex
structure were removed from further consideration.
For each of the model structures, the atomistic contact
component Xji of the scoring system was calculated with the
probability density maps (PDMs) describing the distribution of
amino acid atoms on the surface of the antigen based on atomistic
contact statistics observed in protein interiors. The PDMs were
constructed following the basic idea first developed by Laskowski
et al [45] with substantial modifications to largely eliminate the
distortion of the predicted PDMs due to distributions of the amino
acid sidechain and mainchain dihedral angles (examples of
atomistic density distributions can be viewed via internet –
http://ismblab.genomics.sinica.edu.tw/. Introduction). Briefly,
the amino acid conformations in proteins were classified according
the conformation clusters (Table S6); the PDMs for the protein
atom types (Table S7) were constructed in an amino acid
conformation-dependent manner, while non-interacting atom
pairs were eliminated from the PDMs based on a statistic pairwise
atomistic interaction preference filter (Table S8). The detailed
method for calculating the PDMs is described in full in Text S1.
Figure S1 depicts the flow chart of the computational procedure
for PDMs. The computational tools are available from the
ISMBLab (In Silico Molecular Biology Laboratory) web server:
http://ismblab.genomics.sinica.edu.tw/.
The atomistic contact term Xji(rotamerk) for amino acid i
adopting rotameric conformation k at position j in the CDR of
the antibody was calculated based on a model antibody-VEGF










where amino acid i has n atoms. AVE(PDMm) is the averaged PDM
value corresponding to atom m on the surface of the antigen. This
value was calculated by summing the PDM values corresponding
to the atom m at the grids enclosed in the van der Waals volume of
the atom m and the sum was then divided by the number of grid
points enclosed in the atom to yield AVE(PDMm). pref in Equation
(1) is the reference probability for an atom at a reference point far
apart from the antigen surface. The reference probability must be
smaller than the minimal PDM value (,10
210 in this work) but
cannot equal to zero, so as to avoid singularity in calculating
Xji(rotamerk) when AVE(PDMm) equals to zero. No experimental
data can be used to derive the reference probability, but we found
that when pref is smaller than 10
210, the relative ranking of the
Xji(rotamerk) term is independent to the selection of the reference
probability. Even when the value of the pref is set between 10
28 and
10
210, the correlation of the Xji term with the experimental amino
acid preference Wji does not change. Thus pref=10
210 has been
empirically determined in this work; the correlating the Xji term
with the experimental amino acid preference Wji, as shown in
Table S4, is insensitive to the selection of the pref value.
The hydration-mediated term Yji(rotamerk) for amino acid i
adopting rotamer conformation k at position j in the antibody is
calculated based on the model antibody-antigen complex structure
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where l0 is the grid index for the grid points inside the antigen
molecular volume and PDMo(Ab)l0 is the water oxygen PDM value
at grid point l0; m0 is the grid index for the grid points inside the
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PDM value at grid point m0; l9 is the grid index for the grid points
within the overlapping volume between PDMo(Ab) and PDMo(Ag).
The PDMo(Ab) is the water oxygen PDM on the antibody surface
in the absence of the antigen. The PDMo(Ab) was calculated for the
amino acid i only. The PDMo(Ag) is the water oxygen PDM on the
antigen surface in the absence of the binding antibody. Following
the same rationale as in Equation (1), the reference probability pref
is set at 10
210. Again, the value of pref does not affect the ranking
order of Yji calculated for each amino acid type and rotamer
conformation. The first two negative terms (the terms involving l0
and m0) in the right-hand-side of the equation is the desolvation
terms for removing water from the binding site of the antibody and
the antigen respectively; the positive terms (the terms involving l9)
correspond to the water-mediated interactions – the first positive
term accounts for the interactions between the waters on the
surface of the antibody and the atoms on the surface of the
antigen, and the second positive terms accounts for the
interactions between the waters on the surface of the antigen
and the atoms on the surface of the antibody. The first two
negative desolvation terms are against binding of the antibody and
antigen, while the two positive water-mediated interactions terms
are favorable for the antibody-antigen interactions (hydration
pattern prediction request to http://ismblab.genomics.sinica.edu.
tw/. predict . protein hydration pattern).
The calculation of the structural propensity Zji for amino acid i
in position j has been described in details in a previous paper [46].
Briefly, local structures in PDB similar to the CDR structures
flanking with two stem b-structures in the unbound antibody
structure (2FJF) were collected with PrISM using the threshold of
PSD,0.1[47]; these local structures were multiple-aligned based
on structural similarity with PrISM [46,47,48,49,50]. Zji was
calculated with the structure-based multiple sequence alignments








where Cji is the number of the amino acid i that appears in the
position j of the multiple sequence alignment; pi is the background
probability for amino acid i in proteins; M is the number of rows in
the sequence profile; the term (B+M-Sk=1,20Cjk) is the Bayesian
prediction pseudo-count, where B=M
0.5 is adequate in the
calculation.
Predicted amino acid preference in binary form dpWji for amino











The Xji in Equation (4) is the upper bound of the atomistic contact
term for amino acid i at position j; Xji for each of the rotamer
model structures 1,k (here, k is the total number of rotamers for amino
acid type i) for amino acid i at position j was calculated (Equation
(1)) and the largest Xji in this set of Xji(rotamer1,k) was used in
Equation (4). This term corresponds to the most favourable
contribution from amino acid i at position j to the protein-protein
complex formation. Yji(rotamer1,k) for each of the rotamer model
structures 1,k of amino acid i at position j was calculated
(Equation (2)) and the smallest Yji in this set of Yji(rotamer1,k) was
used in Equation (4). This Yji reflects the maximal desolvation
energy penalty due to the amino acid i at position j in forming the
protein-protein complex; the rotamer conformation with the
maximal desolvation energy penalty is the most favourable
conformation in the hydration environment before forming the
antibody-antigen complex.
At each position j, one logistic regression model was trained for
each of the 20 amino acid types. The weights (xji,yji,zji,aji)i n
Equation (4) for predicting the preference of amino acid type i at
position j were optimized with a logistic regression algorithm in
MATLAB to minimize the difference between pWki in Equation (4)
with Wki from Equation (5) (see below), where k represents all the
positions except for the position j. The optimized weights
(xji,yji,zji,aji) were then applied to Equation (4) to predict pWji for
amino acid type i at position j (i.e., leave-one-out cross validation
approach to mimic the prediction situation). The leave-one-out
training process was carried out through all the 24 positions in this
work. The thresholds ti for the 20 amino acid types were optimized
in the training process to maximize the Matthews correlation
coefficient (MCC, Equation (10)) for the leave-one-out cross
validation predictions.
The experimental amino acid preferences Wji, as shown in
Table 1 and in Table S4 are expressed in half-bit units calculated














dWji=1 when Wji$0; otherwise dWji=0, where Wji is the
preference for amino acid i at position j in the CDR of the
antibody; Cji is the count for amino acid i at position j; M is the
count of VEGF-binding CDR sequences containing position j; pi is
the background probability for amino acid i encoded in the NNK
degenerate codon [51]; the square root of M in the equation is the
pseudo count to prevent singularity when Cij equals to zero. In
practice, positive Wji (observed count for amino acid i at position j
is greater than the anticipated frequency of amino acid i encoded
in the degenerate codon NNK) for amino acid type i is considered
as positive in position j (dWji=1 when Wji$0).
The predictions were assessed by comparing the positives
(dWji=1, see Equation(5)) and negatives (dWji=0, see Equation(5))
with the predicted positives (dpWji=1, see Equation (4) and the
predicted negatives (dpWji=0, see Equation(4)). The predicted
positives are composed of true positives (TP) and false positives
(FP), while the predicted negatives are composed of true negatives
(TN) and false negatives (FN). The accuracy, specificity, recall
(sensitivity), precision and Matthews correlation coefficient (MCC)
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